Emmaus Life Sciences, Inc.: Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

TORRANCE, Calif., March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported

Related Keywords

United Arab Emirates ,Netherlands ,United States ,Saudi Arabia ,Qatar ,Bahrain ,France ,Woman ,Kuwait ,Kingdom Of Saudi Arabia ,Saudi ,Yutaka Niihara ,Willis Lee ,Saudi Food Drug Administration ,Prnewswire Emmaus Life Sciences Inc ,Kainos Medicine Inc ,Emmaus Life Sciences ,Exchange Commission On ,Emmaus Life Sciences Inc ,Company Contact ,Life Sciences ,Chief Executive Officer ,Kainos Medicine ,Saudi Food ,Drug Administration ,Prescribing Information ,Private Securities Litigation Reform Act ,Middle East North Africa ,Middle East ,Annual Report ,Exchange Commission ,Financial Tables Follow ,Consolidated Statements ,Ended December ,Goods Sold ,Stockholder Deficit ,Emmaus ,Life ,Ciences ,Reports ,022 ,Financial ,Results ,Rovides ,Business ,Update ,